Albendazole mechanism of action
Reading File
Finding Sources
Reading File
Reading File
Here is a comprehensive summary of albendazole's mechanism of action based on authoritative pharmacology textbooks:
Albendazole — Mechanism of Action
Albendazole is a benzimidazole (BZ) anthelmintic. Its actions stem from multiple interconnected mechanisms targeting helminth biochemistry:
1. Inhibition of Microtubule Polymerization (Primary Mechanism)
Albendazole binds selectively to β-tubulin in susceptible parasites, blocking its assembly into microtubules. This disrupts the cytoskeleton, impairing cell division, intracellular transport, and structural integrity of the worm.
Selectivity: The drug has a much higher affinity for parasite β-tubulin than for mammalian β-tubulin, which explains its selective toxicity. It does not meaningfully affect human tubulin at therapeutic doses.
2. Inhibition of Glucose Uptake
Albendazole decreases glucose absorption by the worm, depleting glycogen stores. Helminths depend on anaerobic glycolysis for energy, so glucose deprivation leads to progressive energy failure and worm death.
3. Inhibition of Fumarate Reductase
Albendazole inhibits fumarate reductase, a mitochondrial enzyme critical for helminth energy metabolism (anaerobic electron transport chain). This further disrupts ATP generation.
4. Uncoupling of Oxidative Phosphorylation
At the mitochondrial level, benzimidazoles also cause uncoupling of oxidative phosphorylation, compounding the energy deficit.
Active Metabolite: Albendazole Sulfoxide
Albendazole undergoes rapid first-pass hepatic metabolism to albendazole sulfoxide, which is the pharmacologically active form responsible for activity against tissue-dwelling helminths. This metabolite:
- Crosses the blood-brain barrier (CSF levels ~40% of serum)
- Has a serum half-life of 8–9 hours
- Is eliminated primarily renally
- Is metabolized by CYP3A4 in the intestinal mucosa
Summary Table
| Mechanism | Target | Effect |
|---|---|---|
| β-tubulin binding | Parasite cytoskeleton | Blocks microtubule polymerization |
| Glucose uptake inhibition | Worm tegument/gut | Glycogen depletion, energy failure |
| Fumarate reductase inhibition | Mitochondria | Disrupts anaerobic metabolism |
| Uncoupling of oxidative phosphorylation | Mitochondria | Impairs ATP synthesis |
Sources: Goldman-Cecil Medicine, p. 3389; Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 1345; Katzung's Basic and Clinical Pharmacology, 16th Ed.
This is a shared conversation. Sign in to Orris to start your own chat.